Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail Onychomycosis
Launched by NOVARTIS · Apr 11, 2007
Trial Information
Current as of May 16, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male and females 12 - 75 years of age
- • Fungal toenail infection of one or both of the large (great) toenails
- • The nail infection must be due to a dermatophyte, (mixed infections \[dermatophyte and non-dermatophyte\] are not allowed)
- • The target toenail area must have at least 25% to no more than 75% disease involvement without spikes.
- Exclusion Criteria:
- • Target foot must not have severe plantar (moccasin) tinea pedis that would require systemic therapy. Mild to moderate tinea pedis (athlete's foot) infection should be treated with terbinafine prior to baseline or at any time during the trial. Other topical treatments for athlete's foot may be recommended at the discretion of the investigator.
- • Subjects must not have abnormalities of the nail that could prevent a normal appearing nail if clearing of infection is achieved
- • No administration of systemic antifungal medications within 6 months prior to screening visit
- • No application of prescription topical antifungal medications for toenail fungus within 3 months or other commercially available topical medications for toenail fungus applied directly to the toenails within 1 month prior to screening visit
- • Patients with the target toenail involving the matrix (lunula) or having less than 2mm clear (unaffected) nail plate length beyond the proximal fold.
- • Presence of dermatophytoma (defined as thick masses of fungal hyphae and necrotic keratin between the nail plate and nail bed) on the target nail.
- • No professional pedicures or application of any nail polish product or nail cosmetic to the toenails after the screening visit
- • Known pregnancy or lactation at time of enrollment
- • Other protocol-defined inclusion/exclusion criteria may apply
About Novartis
Novartis is a global healthcare company based in Switzerland, dedicated to reimagining medicine to improve and extend people's lives. With a strong focus on innovative pharmaceuticals, Novartis engages in the research, development, and commercialization of a wide range of therapies across various therapeutic areas, including oncology, cardiology, immunology, and neuroscience. The company is committed to advancing clinical research through rigorous trials that prioritize patient safety and efficacy, aiming to deliver groundbreaking treatments and solutions that address unmet medical needs worldwide. Novartis's commitment to innovation and collaboration positions it at the forefront of the biopharmaceutical industry, driving advancements that enhance patient care and health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Various Cities, , France
Various Cities, , Germany
Various Cities, , Iceland
Various Cities, , Finland
Various Cities, , Hungary
Various Cities, , Norway
Various Cities, , Poland
Various Cities, , Russian Federation
Various Cities, , Spain
Various Cities, , Turkey
Patients applied
Trial Officials
Novartis
Study Director
Novartis
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials